{
    "Trade/Device Name(s)": [
        "FLC Kappa",
        "FLC Lambda"
    ],
    "Submitter Information": "Sebia, Inc.",
    "510(k) Number": "K210623",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031016"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFH",
        "DEH"
    ],
    "Summary Letter Date": "August 2, 2022",
    "Summary Letter Received Date": "August 4, 2022",
    "Submission Date": "October 20, 2022",
    "Regulation Number(s)": [
        "21CFR866.5550",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Immunoglobulin (Light Chain Specific) Immunological Test System",
        "Quality Control Material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Kappa free light chain",
        "Lambda free light chain"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Microplate reader (absorbance spectrophotometry at 450 nm)",
        "Microplate"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-Linked Immunosorbent Assay (ELISA)",
        "Sandwich ELISA"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Kit",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Sebia FLC Kappa and FLC Lambda ELISA kits for quantifying free light chains in serum for multiple myeloma and AL amyloidosis diagnosis",
    "Indications for Use Summary": "Intended for quantification of Kappa and Lambda free light chains in human serum from adults by ELISA; aids in the diagnosis of multiple myeloma and AL amyloidosis, to be used with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}